Evolus (EOLS) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Evolus (EOLS) over the past year, gaining 97.5% versus a gain of 24.1%. Over five years, PBYI leads with a +70.1% price change compared with +0.8% for EOLS. Puma Biotechnology is the larger company by market cap ($531.2 million vs $510.6 million), about 1.0 times the size.
On valuation, Evolus trades at a lower forward P/E (26.4x vs 29.4x for Puma Biotechnology).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | PBYI |
|---|---|---|
| Share price | $7.73 | $10.29 |
| Market cap | $510.57M | $531.17M |
| 1-day change | -0.90% | +3.21% |
| YTD return | +16.24% | +72.94% |
| 1-year return | +24.08% | +97.50% |
| 5-year return | +0.78% | +70.08% |
| P/E ratio (TTM) | — | 20.18 |
| Forward P/E | 26.43 | 29.40 |
| EPS (TTM) | $-0.53 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $10.35 |
| 52-week low | $3.86 | $4.58 |
| Distance from 52-week high | -16.97% | -0.58% |
| Analyst consensus | none | none |
| Avg. price target upside | +94.05% | — |
| Average volume | 904.95K | 320.35K |
| Shares outstanding | 66.05M | 51.62M |
| Employees | 353 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed EOLS by 73.4 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
EOLS vs PBYI FAQ
Which is bigger, Evolus or Puma Biotechnology?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $531.17M compared with $510.57M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or PBYI?
PBYI returned +97.50% over the past 12 months, compared with +24.08% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.